Trials / Conditions / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

22 registered clinical trials studyying Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898	Fred Hutchinson Cancer Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Active Not Recruiting	Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277	City of Hope Medical Center	Phase 2
Active Not Recruiting	Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemi NCT03516279	ECOG-ACRIN Cancer Research Group	Phase 2
Withdrawn	Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344	City of Hope Medical Center	Phase 2
Active Not Recruiting	Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Le NCT03654768	SWOG Cancer Research Network	Phase 2
Terminated	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486	Roswell Park Cancer Institute	Phase 2
Completed	Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646	M.D. Anderson Cancer Center	Phase 1
Terminated	Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure NCT02906696	M.D. Anderson Cancer Center	Phase 2
Recruiting	Personalized NK Cell Therapy in CBT NCT02727803	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early NCT02689440	M.D. Anderson Cancer Center	Phase 2
Terminated	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700	Stanford University	Phase 1
Active Not Recruiting	Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933	City of Hope Medical Center	Phase 2
Completed	Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134	City of Hope Medical Center	Phase 2
Unknown	NK Cells in Cord Blood Transplantation NCT01619761	M.D. Anderson Cancer Center	Phase 1
Recruiting	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic P NCT01746836	M.D. Anderson Cancer Center	Phase 2
Completed	Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Re NCT01428635	M.D. Anderson Cancer Center	Phase 2 / Phase 3
Completed	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575	Fred Hutchinson Cancer Center	Phase 2
Completed	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer W NCT00796068	Fred Hutchinson Cancer Center	Phase 2
Completed	Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888	Fred Hutchinson Cancer Center	Phase 2
Completed	Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia NCT00254423	M.D. Anderson Cancer Center	Phase 2
Completed	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478	Fred Hutchinson Cancer Center	Phase 3